Google+
Quote
NAVIGATION
PNHP RESOURCES

Latest PNHP News

  • Posted on Thursday, August 25, 2016
    By Dr. Jen Gunter | Dr. Gunter's Wordpress Blog, August 20, 2016
    Two years ago I wrote about my experience in a London emergency department with my son, Victor. That post has since been viewed > 450,000 times. There are over 800 comments with no trolls (a feat unto itself) and almost all of them express love for the NHS. I was in England again this week. And yes, I was back in an emergency department, but this time with my cousin (who is English). This is what happened.

  • Posted on Tuesday, August 23, 2016
    By Ture Richard Turnbull | Jamaica Plain (Mass.) News, Aug. 22, 2016
    The Boston City Council will take a bold step on Wednesday, August 24, by passing a resolution reaffirming its support for a single-payer health care system. The resolution calls upon the state legislature in the upcoming 2017-2018 legislative session to propose and pass a measure to achieve a single-payer system in the Commonwealth.

  • Posted on Tuesday, August 23, 2016
    By Kay Tillow | The Courier-Journal (Louisville, Ky.), letters, Aug. 23, 2016
    No one should cry for Aetna CEO Mark Bertolini over his claim of losses in the Obamacare exchange plans. Bertolini raked in $27.9 million in total compensation in 2015.

  • Posted on Friday, August 26, 2016
    Although many readers are quite familiar with the concept of adverse selection presented here, the take-home message today is contained in the last three paragraphs of Uwe Reinhardt’s article. By relying on private insurers to control spending, we have driven per capita health care spending up to twice the average of nations with far better health care financing systems.
  • Posted on Thursday, August 25, 2016
    This JAMA article provides a comprehensive explanation as to why pharmaceutical prices are so high in the United States, and they even provide a few suggestions as to what might be done about it. The major error they make is that they assume that the problem should be addressed by US-style quasi-market solutions but not through a government solution that they say “would have major marketplace ramifications and is not at present politically feasible, in part because of the power of the pharmaceutical lobby in Washington, DC.”
  • Posted on Wednesday, August 24, 2016
    Much is being written about Mylan’s price gouging of its life-saving injectable epinephrine - EpiPen - charging over $600 for a product that costs less than a dollar to make, so rather than discussing the background, comments will be limited to the ethical underpinnings of this decision to gouge us.